Plasma asymmetric dimethylarginine and cardiovascular events in patients with acute decompensated heart failure

Translational Research

Volumn 152, Issue 1, 2008, Pages 24-30

  Dückelmann, Christina ^a,b   Mittermayer, Friedrich ^a   Haider, Dominik G ^a   Altenberger, Johann ^c   Wolzt, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b St Johanns Spital   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GLYCOSIDE; LEVOSIMENDAN; LOOP DIURETIC AGENT; N(G),N(G) DIMETHYLARGININE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; XIPAMIDE;

ACUTE DISEASE; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PATIENT MONITORING; PLASMA; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL TIME; UNIVARIATE ANALYSIS; VENOUS BLOOD;

EID: 46349085164     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2008.05.001     Document Type: Article

References (37)

1. Ghali J.K., Cooper R., and Ford E. Trends in hospitalization rates for heart-failure in the United-States, 1973-1986-evidence for increasing population prevalence. Arch Intern Med 150 (1990) 769-773
2. Felker G.M., Adams K.F., Konstam M.A., O'Connor C.M., and Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J 145 (2003) S1825
3. Ball S.G., Cowan J.C., Winter C., et al. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342 (1993) 821-828
4. Cleland J.G., Swedberg K., Follath F., et al. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe-Part 1: patient characteristics and diagnosis. Eur Heart J 24 (2003) 442-463
5. Gackowski A., Isnard R., Golmard J.L., et al. Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J 25 (2004) 1788-1796
6. Brophy J.M., Deslauriers G., Boucher B., and Rouleau J.L. The hospital course and short-term prognosis of patients presenting to the emergency room with decompensated congestive heart failure. Can J Cardiol 9 (1993) 219-224
7. Brophy J.M., Deslauriers G., and Rouleau J.L. Long-term prognosis of patients presenting to the emergency room with decompensated congestive heart failure. Can J Cardiol 10 (1994) 543-547
8. Cheng V., Kazanagra R., Garcia A., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37 (2001) 386-391
9. Logeart D., Thabut G., Jourdain P., et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43 (2004) 635-641
10. Remme W.J., and Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22 (2001) 1527-1560
11. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
12. Nieminen M.S., Bohm M., Cowie M.R., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J 26 (2005) 384-416
13. Vallance P., and Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24 (2004) 1023-1030
14. Achan V., Broadhead M., Malaki M., et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23 (2003) 1455-1459
15. Kielstein J.T., Impraim B., Simmel S., et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109 (2004) 172-177
16. Krzyzanowska K., Mittermayer F., Wolzt M., and Schernthaner G. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with type 2 diabetes. Diabetes Care 30 (2007) 1834-1839
17. Zoccali C., Bode-Böger S.M., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358 (2001) 2113-2117
18. Meinitzer A., Seelhorst U., Wellnitz B., et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (The Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem 53 (2007) 273-283
19. Nijveldt R.J., Teerlink T., Van der Hoven B., et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 22 (2003) 23-30
20. Dückelmann C., Mittermayer F., Haider D.G., Altenberger J., Eichinger J., and Wolzt M. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol 27 (2007) 2037-2042
21. Teerlink T., Nijveldt R.J., de Jong S., and van Leeuwen P.A.M. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 303 (2002) 131-137
22. Mittermayer F., Namiranian K., Pleiner J., Schaller G., and Wolzt M. Acute Escherichia coli endotoxaemia decreases the plasma l-arginine/asymmetrical dimethylarginine ratio in humans. Clin Sci 106 (2004) 577-581
23. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999) 461-470
24. Januzzi J.L., van Kimmenade R., Lainchbury J., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. Eur Heart J 27 (2006) 330-337
25. Saitoh M., Osanai T., Kamada T., et al. High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. Heart Vessels 18 (2003) 177-182
26. Usui M., Matsuoka H., Miyazaki H., Ueda S., Okuda S., and Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 62 (1998) 2425-2430
27. Surdacki A., Nowicki M., Sandmann J., et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33 (1999) 652-658
28. Böger R.H., Bode-Böger S.M., Szuba A., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98 (1998) 1842-1847
29. Gorenflo M., Zheng C.B., Werle E., Fiehn W., and Ulmer H.E. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 37 (2001) 489-492
30. Kielstein J.T., Böger R.H., Bode-Böger S.M., et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10 (1999) 594-600
31. Abbasi F., Asagmi T., Cooke J.P., et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 88 (2001) 1201-1203
32. Böger R.H., Bode-Böger S.M., Thiele W., Junker W., Alexander K., and Frölich J.C. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 95 (1997) 2068-2074
33. Delles C., Schneider M.P., John S., Gekle M., and Schmieder R.E. Angiotensin converting enzyme inhibition and angiotensin II AT(1)-receptor blockade reduce the levels of asymmetrical N-G, N-G-dimethylarginine in human essential hypertension. Am J Hypertens 15 (2002) 590-593
34. Maas R. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc Med 10 (2005) S49-S57
35. Bart B.A., Shaw L.K., McCants Jr. C.B., et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 30 (1997) 1002-1008
36. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342 (2000) 1077-1084
37. Adams K.F., Dunlap S.H., Sueta C.A., et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol 28 (1996) 1781-1788